Download PDF
Semin Thromb Hemost 2017; 43(2): 178-184
DOI: 10.1055/s-0036-1585081
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis

Ton Lisman
1   Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
29 July 2016 (online)

    Permissions and Reprints

Abstract

It has been well established that inherited or acquired hypercoagulability is a risk factor for venous thrombosis. In addition, hypercoagulability may contribute to the risk of arterial events. Much less is known regarding the role of the fibrinolytic system in the risk of thrombotic disease, which partly relates to the lack of validated assays. A plasma-based global fibrinolysis assay, which is sensitive to plasma levels of plasminogen, regulators of fibrinolysis, and proteins involved in coagulation, has been used in large epidemiological studies to assess the role of fibrinolysis in thrombosis. It has been demonstrated that a hypofibrinolytic state increases the risk of a first venous thrombosis, but not of a recurrence. This increased risk of venous thrombosis associated with plasma hypofibrinolysis appears primarily driven by elevated plasma levels of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor type 1. The combination of hypercoagulability and hypofibrinolysis synergistically enhances the risk of a first venous event. Plasma hypofibrinolysis may constitute a risk factor for the postthrombotic syndrome. Decreased fibrinolytic potential is also associated with an increased risk of arterial thrombosis, but only in individuals younger than 55 years. The association between hypofibrinolysis and myocardial infarction appears primarily driven by elevated levels of α2-antiplasmin. Although recent studies have clearly demonstrated a role of the fibrinolytic system in thrombotic disease, the clinical utility of plasma-based clot lysis assays is probably limited.

Keywords

fibrinolysis - venous thrombosis - arterial thrombosis - myocardial infarction - stroke
 

  • References

  • 1 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353 (9159): 1167-1173
    CrossrefPubMedGoogle Scholar
  • 2 Ye Z, Liu EH, Higgins JP , et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367 (9511): 651-658
    CrossrefPubMedGoogle Scholar
  • 3 Boekholdt SM, Kramer MH. Arterial thrombosis and the role of thrombophilia. Semin Thromb Hemost 2007; 33 (6) 588-596
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 de Moerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007; 44 (2) 106-113
    CrossrefPubMedGoogle Scholar
  • 5 Maino A, Rosendaal FR, Algra A, Peyvandi F, Siegerink B. Hypercoagulability is a stronger risk factor for ischaemic stroke than for myocardial infarction: a systematic review. PLoS ONE 2015; 10 (8) e0133523
    CrossrefPubMedGoogle Scholar
  • 6 Schwarz T, Siegert G, Oettler W , et al. Venous thrombosis after long-haul flights. Arch Intern Med 2003; 163 (22) 2759-2764
    CrossrefPubMedGoogle Scholar
  • 7 Mehta R, Shapiro AD. Plasminogen deficiency. Haemophilia 2008; 14 (6) 1261-1268
    CrossrefPubMedGoogle Scholar
  • 8 Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 2008; 122 (6) 736-742
    CrossrefPubMedGoogle Scholar
  • 9 Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 1991; 151 (9) 1721-1731
    CrossrefPubMedGoogle Scholar
  • 10 Prins MH, Hirsh J. A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Am Heart J 1991; 122 (2) 545-551
    CrossrefPubMedGoogle Scholar
  • 11 Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood 1994; 83 (2) 351-356
    CrossrefPubMedGoogle Scholar
  • 12 Wohner N, Sótonyi P, Machovich R , et al. Lytic resistance of fibrin containing red blood cells. Arterioscler Thromb Vasc Biol 2011; 31 (10) 2306-2313
    CrossrefPubMedGoogle Scholar
  • 13 Burnand KG, Gaffney PJ, McGuinness CL, Humphries J, Quarmby JW, Smith A. The role of the monocyte in the generation and dissolution of arterial and venous thrombi. Cardiovasc Surg 1998; 6 (2) 119-125
    CrossrefPubMedGoogle Scholar
  • 14 Zubairova LD, Nabiullina RM, Nagaswami C , et al. Circulating microparticles alter formation, structure, and properties of fibrin clots. Sci Rep 2015; 5: 17611
    CrossrefPubMedGoogle Scholar
  • 15 Rijken DC, Hoegee-de Nobel E, Jie AF, Atsma DE, Schalij MJ, Nieuwenhuizen W. Development of a new test for the global fibrinolytic capacity in whole blood. J Thromb Haemost 2008; 6 (1) 151-157
    PubMedGoogle Scholar
  • 16 Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. J Am Coll Cardiol 2010; 55 (19) 2107-2115
    CrossrefPubMedGoogle Scholar
  • 17 Sharma S, Farrington K, Kozarski R , et al. Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. Eur Heart J 2013; 34 (5) 354-363
    CrossrefPubMedGoogle Scholar
  • 18 Kuiper GJ, Kleinegris MC, van Oerle R , et al. Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity. Thromb J 2016; 14: 1
    CrossrefPubMedGoogle Scholar
  • 19 Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Fibrinolysis and the risk of venous and arterial thrombosis. Curr Opin Hematol 2007; 14 (3) 242-248
    CrossrefPubMedGoogle Scholar
  • 20 Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009; 35 (5) 468-477
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Okafor ON, Gorog DA. Endogenous fibrinolysis: an important mediator of thrombus formation and cardiovascular risk. J Am Coll Cardiol 2015; 65 (16) 1683-1699
    CrossrefPubMedGoogle Scholar
  • 22 Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev 2015; 29 (1) 17-24
    CrossrefPubMedGoogle Scholar
  • 23 von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86 (8) 3035-3042
    PubMedGoogle Scholar
  • 24 Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99 (10) 2323-2327
    CrossrefPubMedGoogle Scholar
  • 25 Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80 (5) 829-835
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Lisman T, Leebeek FW, Mosnier LO , et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121 (1) 131-139
    CrossrefPubMedGoogle Scholar
  • 27 Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004; 103 (6) 2157-2161
    CrossrefPubMedGoogle Scholar
  • 28 Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105 (3) 1102-1105
    CrossrefPubMedGoogle Scholar
  • 29 Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4 (5) 1029-1036
    CrossrefPubMedGoogle Scholar
  • 30 Dunn EJ, Philippou H, Ariëns RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49 (5) 1071-1080
    CrossrefPubMedGoogle Scholar
  • 31 Silva MM, Thelwell C, Williams SC, Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator. J Thromb Haemost 2012; 10 (11) 2354-2360
    CrossrefPubMedGoogle Scholar
  • 32 Foley JH, Nesheim ME. Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2009; 7 (3) 453-459
    CrossrefPubMedGoogle Scholar
  • 33 Colucci M, Binetti BM, Branca MG , et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38 (1) 230-237
    PubMedGoogle Scholar
  • 34 Zucker M, Seligsohn U, Salomon O, Wolberg AS. Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency. J Thromb Haemost 2014; 12 (7) 1121-1130
    CrossrefPubMedGoogle Scholar
  • 35 He S, Antovic A, Blombäck M. A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work. Thromb Res 2001; 103 (5) 355-361
    CrossrefPubMedGoogle Scholar
  • 36 Longstaff C. Shiny app for calculating clot lysis times. https://Drclongstaff.shinyapps.io/clotlysisCL/ . Accessed April 1, 2016
    PubMedGoogle Scholar
  • 37 Meltzer ME, Lisman T, de Groot PG , et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116 (1) 113-121
    CrossrefPubMedGoogle Scholar
  • 38 Meltzer ME, Hasstedt SJ, Vossen CY , et al. Genome scan of clot lysis time and its association with thrombosis in a protein C-deficient kindred. J Thromb Haemost 2011; 9 (7) 1383-1390
    CrossrefPubMedGoogle Scholar
  • 39 Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004; 204 (2) 127-143
    CrossrefPubMedGoogle Scholar
  • 40 Muramatsu T. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad, Ser B, Phys Biol Sci 2010; 86 (4) 410-425
    CrossrefPubMedGoogle Scholar
  • 41 Kojima S, Muramatsu H, Amanuma H, Muramatsu T. Midkine enhances fibrinolytic activity of bovine endothelial cells. J Biol Chem 1995; 270 (16) 9590-9596
    CrossrefPubMedGoogle Scholar
  • 42 Lisman T, Meltzer ME, Cannegieter SC, Rosendaal FR. Plasma levels of midkine (neurite growth-promoting factor 2) are not associated with plasma fibrinolytic potential or risk of venous thrombosis. J Thromb Haemost 2012; 10 (5) 964-966
    CrossrefPubMedGoogle Scholar
  • 43 Meltzer ME, Lisman T, Doggen CJ, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med 2008; 5 (5) e97
    CrossrefPubMedGoogle Scholar
  • 44 Karasu A, Baglin TP, Luddington R, Baglin CA, van Hylckama Vlieg A. Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis. Br J Haematol 2016; 172 (6) 947-953
    CrossrefPubMedGoogle Scholar
  • 45 Undas A, Zawilska K, Ciesla-Dul M , et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114 (19) 4272-4278
    CrossrefPubMedGoogle Scholar
  • 46 Meltzer ME, Bol L, Rosendaal FR, Lisman T, Cannegieter SC. Hypofibrinolysis as a risk factor for recurrent venous thrombosis; results of the LETS follow-up study. J Thromb Haemost 2010; 8 (3) 605-607
    CrossrefPubMedGoogle Scholar
  • 47 Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293 (19) 2352-2361
    CrossrefPubMedGoogle Scholar
  • 48 Traby L, Kollars M, Eischer L, Eichinger S, Kyrle PA. Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study. PLoS ONE 2012; 7 (12) e51447
    CrossrefPubMedGoogle Scholar
  • 49 Ten Cate-Hoek AJ, Henke PK, Wakefield TW. The post thrombotic syndrome: ignore it and it will come back to bite you. Blood Rev 2016; 30 (2) 131-137
    CrossrefPubMedGoogle Scholar
  • 50 Siudut J, Grela M, Wypasek E, Plens K, Undas A. Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome. J Thromb Haemost 2016; 14 (4) 784-793
    CrossrefPubMedGoogle Scholar
  • 51 Bouman AC, McPherson H, Cheung YW , et al. Clot structure and fibrinolytic potential in patients with post thrombotic syndrome. Thromb Res 2016; 137: 85-91
    CrossrefPubMedGoogle Scholar
  • 52 Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol 2009; 145 (1) 121-127
    CrossrefPubMedGoogle Scholar
  • 53 Siegerink B, Meltzer ME, de Groot PG, Algra A, Lisman T, Rosendaal FR. Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO case-control study. Br J Haematol 2012; 156 (2) 252-258
    CrossrefPubMedGoogle Scholar
  • 54 Fredriksson L, Lawrence DA, Medcalf RL. tPA modulation of the blood-brain barrier: a unifying explanation for the pleiotropic effects of tPA in the CNS?. Semin Thromb Hemost 2017; 43 (2) 154-168
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Guimarães AH, de Bruijne EL, Lisman T , et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 2009; 145 (1) 115-120
    CrossrefPubMedGoogle Scholar
  • 56 Leebeek FW, Goor MP, Guimaraes AH , et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 3 (10) 2211-2218
    CrossrefPubMedGoogle Scholar
  • 57 Undas A, Podolec P, Zawilska K , et al. Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke 2009; 40 (4) 1499-1501
    CrossrefPubMedGoogle Scholar
  • 58 Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res 2010; 125 (4) 357-361
    CrossrefPubMedGoogle Scholar
  • 59 Leander K, Blombäck M, Wallén H, He S. Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction. Thromb Haemost 2012; 107 (6) 1092-1099
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood 2010; 116 (4) 529-536
    CrossrefPubMedGoogle Scholar
  • 61 Meltzer ME, Doggen CJ, de Groot PG, Meijers JC, Rosendaal FR, Lisman T. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica 2009; 94 (6) 811-818
    CrossrefPubMedGoogle Scholar
  • 62 Middeldorp S. Is thrombophilia testing useful?. Hematology (Am Soc Hematol Educ Program) 2011; 2011: 150-155
    CrossrefPubMedGoogle Scholar
  • 63 Lisman T, Bakhtiari K, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost 2012; 10 (7) 1312-1319
    CrossrefPubMedGoogle Scholar
  • 64 Lisman T, Leuvenink HG, Porte RJ, Ploeg RJ. Activation of hemostasis in brain dead organ donors: an observational study. J Thromb Haemost 2011; 9 (10) 1959-1965
    CrossrefPubMedGoogle Scholar
  • 65 Kleiss SF, Adelmeijer J, Meijers JC, Porte RJ, Lisman T. A sustained decrease in plasma fibrinolytic potential following partial liver resection or pancreas resection. Thromb Res 2016; 140: 36-40
    CrossrefPubMedGoogle Scholar
  • 66 van Marion AM, Auwerda JJ, Minnema MC , et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost 2005; 94 (6) 1341-1343
    Article in Thieme ConnectPubMedGoogle Scholar
  • 67 Celińska-Lowenhoff M, Iwaniec T, Padjas A, Musiał J, Undas A. Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation. Thromb Haemost 2014; 112 (2) 287-296
    Article in Thieme ConnectPubMedGoogle Scholar
  • 68 Bollen L, Vande Casteele N, Peeters M , et al. The occurrence of thrombosis in inflammatory bowel disease is reflected in the clot lysis profile. Inflamm Bowel Dis 2015; 21 (11) 2540-2548
    CrossrefPubMedGoogle Scholar
  • 69 Konieczynska M, Fil K, Bazanek M, Undas A. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. Thromb Haemost 2014; 111 (4) 685-693
    Article in Thieme ConnectPubMedGoogle Scholar